Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer

Table 3 Clinical and ultrasound responses after completion of chemotherapy

Response	4AC (n = 92)		Weekly docetaxel (n = 41)		3-weekly docetaxel (n = 41)		P-value
	No.	%	No.	%	No.	%
Clinical response
cCR	17	18	26	63	22	54	0.70
cPR	41	45	12	29	15	37
cSD	31	34	1	3	3	7
cPD	1	1	2	5	1	2
NA	2	2	0	0	0	0.0
ORR	58	63	38	93	37	90
US response
cCR	16	19	12	29	12	29	0.71
cPR	37	40	21	51	17	41
cSD	27	29	7	17	8	20
cPD	2	2	0	0.0	0	0
NA	9	10	1	3	4	10
ORR	53	59	33	81	29	71

Abbreviations: AC, doxorubicin+cyclophosphamide; cCR, clinical complete response; cPR, clinical partial response; cSD, clinical stable disease; cPD, clinical progressive disease; NA, not assessable; ORR, overall response rate (cCR+cPR); US, ultrasound

ISSN: 1471-2407